The first protein drug extracted from the milk of a genetically modified animal has finally received European approval.

Scientists from the University of Birmingham, UK, have powered a fuel cell from confectionary waste. They now want to form a consortium with investors and SMEs to apply for an EU Framework grant.

Advances in neuroscience are opening up the treatment options for central nervous system diseases - at the same time as the ageing population is increasing the market for these products.

Drug companies finally have an incentive to carry out safety testing in children following new EU legislation approved last week.

The Open Source software movement has broken the stranglehold of expensive, proprietary products. Could the same thing happen in biotechnology?

Microsoft Corp. is spinning out some of its software technology to two small European tech ventures, as part of a program to speed development of innovations from its labs.

Fujeribio Diagnostics, Inc., based in Japan, has bought Swedish CanAg Diagnostics, merging two leading biotechnology companies in cancer diagnosis.

Europabio thinks that Europe is doing a poor job when it comes to investing in biotechnology.

On May 26, the US Patent Office issued a preliminary ruling on another long-running patent fight. This battle differs from other high-profile clashes as the challenger is taking on not a big corporate entity, but a broad community of IT researchers and academics.

The European Commission wants businesses to spend more on research and development - and to help encourage that, the agency is preparing a volley of government proposals for the Autumn.